Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study
FS Macaluso, W Fries, S Renna… - United European …, 2020 - journals.sagepub.com
Background Biologically naïve patients with inflammatory bowel disease treated with
vedolizumab (VDZ) are largely underrepresented in real-world cohorts. A multi-centre …
vedolizumab (VDZ) are largely underrepresented in real-world cohorts. A multi-centre …
Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study
FS Macaluso, W Fries, S Renna, A Viola… - UNITED EUROPEAN …, 2020 - iris.unime.it
Biologically naïve patients with inflammatory bowel disease treated with vedolizumab (VDZ)
are largely underrepresented in real-world cohorts. A multi-centre, observational cohort …
are largely underrepresented in real-world cohorts. A multi-centre, observational cohort …
Effectiveness and safety of vedolizumab in biologically naïve patients: A real‐world multi‐centre study
FS Macaluso, W Fries, S Renna, A Viola… - UEG …, 2020 - Wiley Online Library
Background Biologically naïve patients with inflammatory bowel disease treated with
vedolizumab (VDZ) are largely underrepresented in real‐world cohorts. A multi‐centre …
vedolizumab (VDZ) are largely underrepresented in real‐world cohorts. A multi‐centre …
Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study
FS Macaluso, W Fries, S Renna… - United European …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Biologically naïve patients with inflammatory bowel disease treated with
vedolizumab (VDZ) are largely underrepresented in real-world cohorts. A multi-centre …
vedolizumab (VDZ) are largely underrepresented in real-world cohorts. A multi-centre …
[HTML][HTML] Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study
FS Macaluso, W Fries, S Renna, A Viola… - United European …, 2020 - ncbi.nlm.nih.gov
Background Biologically naïve patients with inflammatory bowel disease treated with
vedolizumab (VDZ) are largely underrepresented in real-world cohorts. A multi-centre …
vedolizumab (VDZ) are largely underrepresented in real-world cohorts. A multi-centre …
Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study.
FS Macaluso, W Fries, S Renna, A Viola… - United European …, 2020 - europepmc.org
Background Biologically naïve patients with inflammatory bowel disease treated with
vedolizumab (VDZ) are largely underrepresented in real-world cohorts. A multi-centre …
vedolizumab (VDZ) are largely underrepresented in real-world cohorts. A multi-centre …